;PMID: 2659902 ;source_file_1181.mrg ;Release 0.9 of PennBioIE ;Funded by NSF ITR EIA-0205448 ;0)section:[e:0..29] = [t:0..29] ;1)sentence:[e:34..148] = [t:34..148] ;2)section:[e:152..197] = [t:152..197] ;3)section:[e:201..274] = [t:201..274] ;4)sentence:[e:278..444] = [t:278..444] ;5)sentence:[e:445..656] = [t:445..656] ;6)sentence:[e:657..815] = [t:657..815] ;7)sentence:[e:816..936] = [t:816..936] ;8)sentence:[e:937..1079] = [t:937..1079] ;9)sentence:[e:1080..1165] = [t:1080..1165] ;10)section:[e:1169..1213] = [t:1169..1213] ;section 0 Span:0..29 ;Leukemia 1989 Jul;3(7):511-5 (SEC (FRAG (NNP:[0..8] Leukemia) (CD:[10..14] 1989) (.:[15..21] Jul;3-LRB-) (CD:[21..23] 7-RRB-) (CD:[23..27] :511) (HYPH:[27..28] -) (CD:[28..29] 5))) ;sentence 1 Span:34..148 ;c-myc amplification coexistent with activating N-ras point mutation in the ;biphenotypic leukemic cell line RED-3. ;[34..39]:gene-rna:"c-myc" ;[40..53]:variation-type:"amplification" ;[81..86]:gene-rna:"N-ras" ;[87..101]:variation-type:"point mutation" ;[123..147]:malignancy:"leukemic cell line RED-3" (SENT (NP-HLN (NP (NN:[34..39] c-myc) (NN:[40..53] amplification)) (ADJP (JJ:[54..64] coexistent) (PP (IN:[65..69] with) (NP (VBG:[70..80] activating) (NN:[81..86] N-ras) (NN:[87..92] point) (NN:[93..101] mutation)))) (PP-LOC (IN:[102..104] in) (NP (NP (DT:[105..108] the) (JJ:[110..122] biphenotypic) (JJ:[123..131] leukemic) (NN:[132..136] cell) (NN:[137..141] line)) (NP (NN:[142..147] RED-3)))) (.:[147..148] .))) ;section 2 Span:152..197 ;Mallet MK, Mane SM, Meltzer SJ, Needleman SW. (SEC (FRAG (NNP:[152..158] Mallet) (NNP:[159..161] MK) (,:[161..162] ,) (NNP:[163..167] Mane) (NNP:[168..170] SM) (,:[170..171] ,) (NNP:[172..179] Meltzer) (NNP:[180..182] SJ) (,:[182..183] ,) (NNP:[184..193] Needleman) (NNP:[194..197] SW.))) ;section 3 Span:201..274 ;Department of Medicine, University of Maryland Hospital, Baltimore 21201. (SEC (FRAG (NNP:[201..211] Department) (IN:[212..214] of) (NNP:[215..223] Medicine) (,:[223..224] ,) (NNP:[225..235] University) (IN:[236..238] of) (NNP:[239..247] Maryland) (NNP:[248..256] Hospital) (,:[256..257] ,) (NNP:[258..267] Baltimore) (.:[268..273] 21201) (.:[273..274] .))) ;sentence 4 Span:278..444 ;While activation of the protooncogene c-N-ras is observed regularly in acute ;myelogenous leukemia, amplification of c-myc in AML cells or derived lines is ; uncommon. ;[316..323]:gene-rna:"c-N-ras" ;[349..376]:malignancy:"acute myelogenous leukemia" ;[378..391]:variation-type:"amplification" ;[395..400]:gene-rna:"c-myc" ;[404..407]:malignancy:"AML" (SENT (S (SBAR-ADV (IN:[278..283] While) (S (NP-SBJ-1 (NP (NN:[284..294] activation)) (PP (IN:[295..297] of) (NP (NP (DT:[298..301] the) (NN:[302..315] protooncogene)) (NP (NN:[316..323] c-N-ras))))) (VP (VBZ:[324..326] is) (VP (VBN:[327..335] observed) (NP-1 (-NONE-:[335..335] *)) (ADVP-TMP (RB:[336..345] regularly)) (PP (IN:[346..348] in) (NP (JJ:[349..354] acute) (JJ:[356..367] myelogenous) (NN:[368..376] leukemia))))))) (,:[376..377] ,) (NP-SBJ (NP (NN:[378..391] amplification)) (PP (IN:[392..394] of) (NP (NN:[395..400] c-myc))) (PP-LOC (IN:[401..403] in) (NP (NP (NN:[404..407] AML) (NNS:[408..413] cells)) (CC:[414..416] or) (NP (VBN:[417..424] derived) (NNS:[425..430] lines))))) (VP (VBZ:[431..433] is) (ADJP-PRD (JJ:[435..443] uncommon))) (.:[443..444] .))) ;sentence 5 Span:445..656 ;In particular, concurrent ras/myc activation, which has been shown to be ;critical in several elegant models of malignancy, has been demonstrated in a ;very small number of human tumors or derivative cell lines. ;[471..474]:gene-rna:"ras" ;[475..478]:gene-rna:"myc" (SENT (S (PP (IN:[445..447] In) (NP (JJ:[448..458] particular))) (,:[458..459] ,) (NP-SBJ-3 (NP (JJ:[460..470] concurrent) (NML (NML (NN:[471..474] ras) (NML-1 (-NONE-:[474..474] *P*))) (SYM:[474..475] /) (NML (NN:[475..478] myc) (NML-1 (NN:[479..489] activation))))) (,:[489..490] ,) (SBAR (WHNP-2 (WDT:[491..496] which)) (S (NP-SBJ-2 (-NONE-:[496..496] *T*)) (VP (VBZ:[497..500] has) (VP (VBN:[501..505] been) (VP (VBN:[506..511] shown) (S (NP-SBJ-2 (-NONE-:[511..511] *)) (VP (TO:[512..514] to) (VP (VB:[516..518] be) (ADJP-PRD (JJ:[519..527] critical)) (PP (IN:[528..530] in) (NP (NP (JJ:[531..538] several) (JJ:[539..546] elegant) (NNS:[547..553] models)) (PP (IN:[554..556] of) (NP (NN:[557..567] malignancy)))))))))))))) (,:[567..568] ,) (VP (VBZ:[569..572] has) (VP (VBN:[573..577] been) (VP (VBN:[578..590] demonstrated) (NP-3 (-NONE-:[590..590] *)) (PP-LOC (IN:[591..593] in) (NP (NP (DT:[594..595] a) (ADJP (RB:[597..601] very) (JJ:[602..607] small)) (NN:[608..614] number)) (PP (IN:[615..617] of) (NP (NP (JJ:[618..623] human) (NNS:[624..630] tumors)) (CC:[631..633] or) (NP (JJ:[634..644] derivative) (NN:[645..649] cell) (NNS:[650..655] lines))))))))) (.:[655..656] .))) ;sentence 6 Span:657..815 ;A cell line, RED-3, is described which was derived from cells of a patient ;with aggressive acute leukemia which exhibits many markers of lineage ;infidelity. ;[670..675]:malignancy:"RED-3" ;[738..764]:malignancy:"aggressive acute leukemia" (SENT (S (NP-SBJ-4 (NP (NP (DT:[657..658] A) (NN:[659..663] cell) (NN:[664..668] line)) (,:[668..669] ,) (NP (NN:[670..675] RED-3))) (SBAR-1 (-NONE-:[675..675] *ICH*))) (,:[675..676] ,) (VP (VBZ:[678..680] is) (VP (VBN:[681..690] described) (NP-4 (-NONE-:[690..690] *)) (SBAR-1 (WHNP-3 (WDT:[691..696] which)) (S (NP-SBJ-3 (-NONE-:[696..696] *T*)) (VP (VBD:[697..700] was) (VP (VBN:[701..708] derived) (NP-3 (-NONE-:[708..708] *)) (PP (IN:[709..713] from) (NP (NP (NNS:[714..719] cells)) (PP (IN:[720..722] of) (NP (NP (DT:[723..724] a) (NN:[725..732] patient)) (PP (IN:[733..737] with) (NP (NP (JJ:[738..748] aggressive) (JJ:[749..754] acute) (NN:[756..764] leukemia)) (SBAR (WHNP-2 (WDT:[765..770] which)) (S (NP-SBJ-2 (-NONE-:[770..770] *T*)) (VP (VBZ:[771..779] exhibits) (NP (NP (JJ:[780..784] many) (NNS:[785..792] markers)) (PP (IN:[793..795] of) (NP (NN:[796..803] lineage) (NN:[804..814] infidelity))))))))))))))))))) (.:[814..815] .))) ;sentence 7 Span:816..936 ;DNA from this cell line contains an activating point mutation of c-N-ras as ;well as 20-30-fold amplification of c-myc. ;[864..878]:variation-type:"point mutation" ;[882..889]:gene-rna:"c-N-ras" ;[913..926]:variation-type:"amplification" ;[930..935]:gene-rna:"c-myc" (SENT (S (NP-SBJ (NP (NN:[816..819] DNA)) (PP (IN:[820..824] from) (NP (DT:[825..829] this) (NN:[830..834] cell) (NN:[836..840] line)))) (VP (VBZ:[841..849] contains) (NP (NP (NP (DT:[850..852] an) (VBG:[853..863] activating) (NN:[864..869] point) (NN:[870..878] mutation)) (PP (IN:[879..881] of) (NP (NN:[882..889] c-N-ras)))) (CONJP (RB:[890..892] as) (RB:[893..897] well) (IN:[898..900] as)) (NP (NP (QP (QP (CD:[901..903] 20) (HYPH:[903..904] -) (CD:[904..906] 30)) (HYPH:[906..907] -) (JJ:[907..911] fold)) (NN:[913..926] amplification)) (PP (IN:[927..929] of) (NP (NN:[930..935] c-myc)))))) (.:[935..936] .))) ;sentence 8 Span:937..1079 ;After HL-60, this is the second example of ras/myc activation in AML derived ;cells and demonstrates that this lesion is not unique to HL-60. ;[943..948]:malignancy:"HL-60" ;[980..983]:gene-rna:"ras" ;[984..987]:gene-rna:"myc" ;[1003..1006]:malignancy:"AML" ;[1043..1054]:malignancy:"this lesion" ;[1073..1078]:malignancy:"HL-60" (SENT (S (PP (IN:[937..942] After) (NP (NN:[943..948] HL-60))) (,:[948..949] ,) (NP-SBJ (DT:[950..954] this)) (VP (VP (VBZ:[955..957] is) (NP-PRD (NP (DT:[958..961] the) (JJ:[962..968] second) (NN:[969..976] example)) (PP (IN:[977..979] of) (NP (NP (NN:[980..983] ras) (NML-1 (-NONE-:[983..983] *P*))) (SYM:[983..984] /) (NP (NN:[984..987] myc) (NML-1 (NN:[989..999] activation)))))) (PP-LOC (IN:[1000..1002] in) (NP (ADJP (NN:[1003..1006] AML) (VBN:[1007..1014] derived)) (NNS:[1015..1020] cells)))) (CC:[1021..1024] and) (VP (VBZ:[1025..1037] demonstrates) (SBAR (IN:[1038..1042] that) (S (NP-SBJ (DT:[1043..1047] this) (NN:[1048..1054] lesion)) (VP (VBZ:[1055..1057] is) (ADJP-PRD (RB:[1058..1061] not) (JJ:[1062..1068] unique) (PP (TO:[1070..1072] to) (NP (NN:[1073..1078] HL-60))))))))) (.:[1078..1079] .))) ;sentence 9 Span:1080..1165 ;Rather, it may be important in leukemogenesis in a small proportion of AML ;patients. ;[1152..1155]:malignancy:"AML" (SENT (S (ADVP (RB:[1080..1086] Rather)) (,:[1086..1087] ,) (NP-SBJ (PRP:[1088..1090] it)) (VP (MD:[1091..1094] may) (VP (VB:[1095..1097] be) (ADJP-PRD (JJ:[1098..1107] important)) (PP (IN:[1108..1110] in) (NP (NN:[1111..1125] leukemogenesis))) (PP-LOC (IN:[1126..1128] in) (NP (NP (DT:[1129..1130] a) (JJ:[1131..1136] small) (NN:[1137..1147] proportion)) (PP (IN:[1148..1150] of) (NP (NN:[1152..1155] AML) (NNS:[1156..1164] patients))))))) (.:[1164..1165] .))) ;section 10 Span:1169..1213 ;PMID: 2659902 [PubMed - indexed for MEDLINE] (SEC (FRAG (NNP:[1169..1173] PMID) (::[1173..1174] :) (CD:[1175..1182] 2659902) (IN:[1183..1184] -LSB-) (NNP:[1184..1190] PubMed) (HYPH:[1191..1192] -) (JJ:[1193..1200] indexed) (IN:[1201..1204] for) (NNP:[1205..1213] MEDLINE-RSB-)))